688317 之江生物
已收盘 02-06 15:00:01
资讯
新帖
简况
每周股票复盘：之江生物（688317）回购股份达总股本1.01%
证券之星 · 03:16
每周股票复盘：之江生物（688317）回购股份达总股本1.01%
之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份比例达到总股本1%暨回购进展公告，2月2日股价下跌5.05%
证券之星 · 02-02
之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份比例达到总股本1%暨回购进展公告，2月2日股价下跌5.05%
每周股票复盘：之江生物（688317）因股价涨幅达15%登龙虎榜
证券之星 · 02-01
每周股票复盘：之江生物（688317）因股价涨幅达15%登龙虎榜
1月26日之江生物（688317）龙虎榜数据：机构净买入1794.7万元
证券之星 · 01-26
1月26日之江生物（688317）龙虎榜数据：机构净买入1794.7万元
异动快报：之江生物（688317）1月26日9点44分触及涨停板
证券之星 · 01-26
异动快报：之江生物（688317）1月26日9点44分触及涨停板
每周股票复盘：之江生物（688317）2025年净利预亏3200万至4700万元
证券之星 · 01-25
每周股票复盘：之江生物（688317）2025年净利预亏3200万至4700万元
之江生物（688317）披露2025年年度业绩预告，1月22日股价下跌0.05%
证券之星 · 01-22
之江生物（688317）披露2025年年度业绩预告，1月22日股价下跌0.05%
之江生物(688317.SH)发预亏，预计2025年度归母净亏损3200万元-4700万元
智通财经 · 01-22
之江生物(688317.SH)发预亏，预计2025年度归母净亏损3200万元-4700万元
之江生物（688317）披露公司产品获得相关认证，01月20日股价下跌0.24%
证券之星 · 01-20
之江生物（688317）披露公司产品获得相关认证，01月20日股价下跌0.24%
之江生物最新公告：公司产品获得马来西亚医疗器械认证
证券之星 · 01-20
之江生物最新公告：公司产品获得马来西亚医疗器械认证
每周股票复盘：之江生物（688317）回购股份181.29万股
证券之星 · 01-11
每周股票复盘：之江生物（688317）回购股份181.29万股
之江生物（688317）披露关于2025年第三次以集中竞价交易方式回购公司股份的进展公告，01月05日股价上涨3.72%
证券之星 · 01-05
之江生物（688317）披露关于2025年第三次以集中竞价交易方式回购公司股份的进展公告，01月05日股价上涨3.72%
之江生物（688317）披露关于变更签字注册会计师及项目质量控制复核人的公告，12月17日股价上涨0.05%
证券之星 · 2025-12-17
之江生物（688317）披露关于变更签字注册会计师及项目质量控制复核人的公告，12月17日股价上涨0.05%
之江生物（688317）披露关于开立募集资金专户并签订募集资金专户监管协议的公告，12月9日股价下跌1.32%
证券之星 · 2025-12-09
之江生物（688317）披露关于开立募集资金专户并签订募集资金专户监管协议的公告，12月9日股价下跌1.32%
之江生物（688317）披露回购股份进展公告，12月2日股价下跌1.56%
证券之星 · 2025-12-02
之江生物（688317）披露回购股份进展公告，12月2日股价下跌1.56%
之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份的进展公告，11月24日股价上涨2.08%
证券之星 · 2025-11-24
之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份的进展公告，11月24日股价上涨2.08%
每周股票复盘：之江生物（688317）股东会通过外汇衍生品交易议案
证券之星 · 2025-11-16
每周股票复盘：之江生物（688317）股东会通过外汇衍生品交易议案
之江生物（688317）披露公司开展外汇衍生品交易业务议案获股东会通过，11月14日股价上涨3.07%
证券之星 · 2025-11-14
之江生物（688317）披露公司开展外汇衍生品交易业务议案获股东会通过，11月14日股价上涨3.07%
之江生物（688317）披露首次回购股份进展，11月03日股价下跌0.91%
证券之星 · 2025-11-03
之江生物（688317）披露首次回购股份进展，11月03日股价下跌0.91%
三友生物与之江生物签署创新生物医药自动化研发战略合作协议
美股速递 · 2025-11-03
三友生物与之江生物签署创新生物医药自动化研发战略合作协议
加载更多
公司概况
公司名称：
上海之江生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-01-18
主营业务：
上海之江生物科技股份有限公司的主营业务是分子诊断试剂和仪器设备的研发、生产和销售。公司的主要产品是分子诊断试剂和仪器设备。公司共有500多项产品，已形成20大系列，是国内感染性疾病分子诊断产品最为齐全的企业之一，覆盖了绝大多数国家法定传染病。
发行价格：
43.22
{"stockData":{"symbol":"688317","market":"SH","secType":"STK","nameCN":"之江生物","latestPrice":21.55,"timestamp":1770361201000,"preClose":21.48,"halted":0,"volume":3411312,"delay":0,"changeRate":0.0033,"floatShares":192000000,"shares":192000000,"eps":-0.7486,"marketStatus":"已收盘","change":0.07,"latestTime":"02-06 15:00:01","open":21.48,"high":21.9,"low":21.48,"amount":73845500,"amplitude":0.0196,"askPrice":21.56,"askSize":76,"bidPrice":21.55,"bidSize":18,"shortable":0,"etf":0,"ttmEps":-0.7486,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":21.48,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":23.63,"lowLimit":19.33,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":192157999,"isCdr":false,"pbRate":1.22,"roa":"--","roe":"--","epsLYR":-0.67,"committee":0.2,"marketValue":4141000000,"turnoverRate":0.0178,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-02-09。","afterMarket":{"amount":0,"volume":0,"close":21.55,"buyVolume":0,"sellVolume":0,"time":1770363237558,"indexStatus":"已收盘 02-06 15:30:00","preClose":21.48},"floatMarketCap":4141000000},"requestUrl":"/m/hq/s/688317","defaultTab":"news","newsList":[{"id":"2609264705","title":"每周股票复盘：之江生物（688317）回购股份达总股本1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609264705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609264705?lang=zh_cn&edition=full","pubTime":"2026-02-08 03:16","pubTimestamp":1770491771,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，之江生物报收于21.55元，较上周的22.75元下跌5.27%。本周，之江生物2月2日盘中最高价报22.6元。截至2026年1月30日，公司累计回购股份1,940,434股，占公司总股本的1.01%，已支付金额41,869,022.21元，回购价格区间为19.58元/股至23.49元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2608930867","title":"之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份比例达到总股本1%暨回购进展公告，2月2日股价下跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608930867","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608930867?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:14","pubTimestamp":1770041672,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，之江生物报收于21.6元，较前一交易日下跌5.05%，最新总市值为41.51亿元。近日，之江生物发布《关于2025年第三次以集中竞价交易方式回购公司股份比例达到总股本1%暨回购进展公告》。截至2026年1月30日，公司累计回购股份1,940,434股，占公司总股本的1.01%，已支付金额41,869,022.21元，回购价格区间为19.58元/股至23.49元/股。本次回购符合相关法规及公司方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2608591070","title":"每周股票复盘：之江生物（688317）因股价涨幅达15%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2608591070","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608591070?lang=zh_cn&edition=full","pubTime":"2026-02-01 04:02","pubTimestamp":1769889740,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，之江生物报收于22.75元，较上周的21.29元上涨6.86%。本周，之江生物1月27日盘中最高价报28.58元。1月30日盘中最低价报22.43元。本周共计1次涨停收盘，无跌停收盘情况。之江生物当前最新总市值43.72亿元，在医疗器械板块市值排名87/127，在两市A股市值排名3858/5184。本周关注点来自交易信息汇总：之江生物因日收盘价格涨幅达到15%登上龙虎榜。此次是近5个交易日内第1次上榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2606021915","title":"1月26日之江生物（688317）龙虎榜数据：机构净买入1794.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606021915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606021915?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:28","pubTimestamp":1769423302,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年1月26日公布的交易公开信息显示，之江生物因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年1月26日收盘，之江生物报收于25.55元，上涨20.01%，涨停，换手率7.02%，成交量13.5万手，成交额3.36亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入1794.7万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600025359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2606267844","title":"异动快报：之江生物（688317）1月26日9点44分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2606267844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606267844?lang=zh_cn&edition=full","pubTime":"2026-01-26 09:46","pubTimestamp":1769391981,"startTime":"0","endTime":"0","summary":"证券之星1月26日盘中消息，9点44分之江生物触及涨停板。其所属行业医疗器械目前上涨。领涨股为之江生物。该股为猴痘概念，肝炎概念，体外诊断概念热股，当日猴痘概念概念上涨1.06%，肝炎概念概念上涨0.55%，体外诊断概念上涨0.12%。1月23日的资金流向数据方面，主力资金净流入31.9万元，占总成交额1.01%，游资资金净流出237.26万元，占总成交额7.51%，散户资金净流入205.35万元，占总成交额6.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600004397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2606237527","title":"每周股票复盘：之江生物（688317）2025年净利预亏3200万至4700万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606237527","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606237527?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:34","pubTimestamp":1769283252,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，之江生物报收于21.29元，较上周的20.7元上涨2.85%。本周，之江生物1月23日盘中最高价报21.35元。之江生物当前最新总市值40.91亿元，在医疗器械板块市值排名94/127，在两市A股市值排名4097/5182。公司公告汇总：之江生物全自动核酸提取仪获马来西亚认证，有效期至2030年12月3日。业绩披露要点之江生物发布业绩预告，预计2025年全年归属净利润亏损3200万元至4700万元。预计2025年扣非后净利润亏损3900万元至5800万元，同比减亏54.78%至69.60%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2605490338","title":"之江生物（688317）披露2025年年度业绩预告，1月22日股价下跌0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605490338","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605490338?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:47","pubTimestamp":1769093231,"startTime":"0","endTime":"0","summary":"截至2026年1月22日收盘，之江生物报收于20.86元，较前一交易日下跌0.05%，最新总市值为40.08亿元。该股当日开盘20.86元，最高20.96元，最低20.76元，成交额达1733.51万元，换手率为0.43%。公司近日发布公告，披露2025年年度业绩预告。公告显示，上海之江生物科技股份有限公司预计2025年年度归属于母公司所有者的净利润为-3,200.00万元到-4,700.00万元，同比减亏63.13%到74.89%；扣除非经常性损益后的净利润为-3,900.00万元到-5,800.00万元，同比减亏54.78%到69.60%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200041266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2605468021","title":"之江生物(688317.SH)发预亏，预计2025年度归母净亏损3200万元-4700万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605468021","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605468021?lang=zh_cn&edition=full","pubTime":"2026-01-22 15:36","pubTimestamp":1769067414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，之江生物(688317.SH)发布2025年年度业绩预告，预计实现归属于母公司所有者的净利润-3,200万元到-4,700万元。与上年同期相比，净利润将减少亏损8,046.21万元到9,546.21万元，同比减亏幅度63.13%到74.89%。报告期公司业绩亏损的主要原因：公司主要产品销量下降、集采政策陆续执行导致价格下降和自产试剂产品增值税税率调整为13%导致收入下降;财务收益的下降和汇兑损益减少等原因导致业绩亏损。同时公司在积极应对市场竞争情况，加强产品研发，优化降本增效举措，挖掘潜力，不断提高产品的市场竞争力，提升公司经营能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"之江生物(688317.SH)发预亏，预计2025年度归母净亏损3200万元-4700万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2604311102","title":"之江生物（688317）披露公司产品获得相关认证，01月20日股价下跌0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604311102","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604311102?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:42","pubTimestamp":1768920134,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘，之江生物报收于20.47元，较前一交易日下跌0.24%，最新总市值为39.33亿元。该股当日开盘20.53元，最高20.82元，最低20.31元，成交额达3072.27万元，换手率为0.78%。近日，之江生物发布关于自愿披露公司产品获得相关认证的公告。公告显示，上海之江生物科技股份有限公司全资子公司上海之江生物医药科技有限公司的全自动核酸提取仪获得马来西亚医疗器械管理局认证，认证编号IVDA3676725-218479，有效期至2030年12月3日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000039989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2604751167","title":"之江生物最新公告：公司产品获得马来西亚医疗器械认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2604751167","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604751167?lang=zh_cn&edition=full","pubTime":"2026-01-20 15:42","pubTimestamp":1768894936,"startTime":"0","endTime":"0","summary":"之江生物(688317.SH)公告称，公司全资子公司上海之江生物医药科技有限公司的全自动核酸提取仪（EX3600）近期获得马来西亚医疗器械管理局认证，可在马来西亚进行销售。该认证有助于提升公司国际竞争力，并推动海外销售产品品类及国际业务拓展。然而，产品面临市场竞争风险，且其销售额及利润贡献存在较大不确定性，对公司整体收入的影响也存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000018730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","159883","BK1583","BK1574","BK1222","09997","BK0239","BK1100","688317"],"gpt_icon":0},{"id":"2602953675","title":"每周股票复盘：之江生物（688317）回购股份181.29万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602953675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602953675?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:21","pubTimestamp":1768076467,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，之江生物报收于21.19元，较上周的20.17元上涨5.06%。本周，之江生物1月8日盘中最高价报21.24元。本周关注点公司公告汇总：之江生物累计回购股份181.29万股，占公司总股本的0.94%。截至2025年12月31日，累计回购股份181.29万股，占公司总股本的0.94%，已支付资金总额3,913.02万元，实际回购价格区间为19.58元/股至22.86元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2601000873","title":"之江生物（688317）披露关于2025年第三次以集中竞价交易方式回购公司股份的进展公告，01月05日股价上涨3.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601000873?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:10","pubTimestamp":1767607828,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，之江生物报收于20.92元，较前一交易日上涨3.72%，最新总市值为40.2亿元。该股当日开盘20.17元，最高20.98元，最低20.17元，成交额达4144.51万元，换手率为1.04%。公告显示，上海之江生物科技股份有限公司于2025年10月15日启动股份回购，回购期限为2025年10月15日至2026年10月14日，拟回购金额为6,000万元至12,000万元，用于员工持股计划或股权激励。2025年12月单月回购71.92万股，支付资金1,496.93万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500027803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2592916136","title":"之江生物（688317）披露关于变更签字注册会计师及项目质量控制复核人的公告，12月17日股价上涨0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592916136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592916136?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:40","pubTimestamp":1765982422,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，之江生物报收于20.12元，较前一交易日上涨0.05%，最新总市值为38.66亿元。近日，之江生物发布公告称，因原签字注册会计师王雪芬离职及内部工作调整，中汇会计师事务所变更公司2025年度审计项目的签字注册会计师及质量控制复核人。变更后，项目合伙人为刘木勇，签字注册会计师为刘木勇和朱启，质量控制复核人为施伟岑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700040288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2590312322","title":"之江生物（688317）披露关于开立募集资金专户并签订募集资金专户监管协议的公告，12月9日股价下跌1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590312322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590312322?lang=zh_cn&edition=full","pubTime":"2025-12-09 17:50","pubTimestamp":1765273842,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘，之江生物报收于20.88元，较前一交易日下跌1.32%，最新总市值为40.12亿元。该股当日开盘21.12元，最高21.25元，最低20.88元，成交额达1820.25万元，换手率为0.45%。公司近日发布公告称，为规范募集资金管理，保护投资者权益，上海之江生物科技股份有限公司已开立募集资金专户并签订《募集资金专户存储四方监管协议》。公司、子公司、招商银行及保荐机构国泰海通证券共同签署监管协议，明确各方责任与义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900028193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"gpt_icon":0},{"id":"2588313380","title":"之江生物（688317）披露回购股份进展公告，12月2日股价下跌1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588313380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588313380?lang=zh_cn&edition=full","pubTime":"2025-12-02 17:54","pubTimestamp":1764669289,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，之江生物报收于21.47元，较前一交易日下跌1.56%，最新总市值为41.26亿元。该股当日开盘21.91元，最高21.91元，最低21.4元，成交额达2100.39万元，换手率为0.51%。公司近日发布关于2025年第三次以集中竞价交易方式回购公司股份的进展公告。截至2025年11月28日，公司累计回购股份1,093,704股，占总股本0.57%，已支付金额24,160,914.13元，回购价格区间为21.52元/股至22.86元/股。本次回购符合相关规定及方案要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200027316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2585009468","title":"之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份的进展公告，11月24日股价上涨2.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585009468","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585009468?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:00","pubTimestamp":1763978449,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，之江生物报收于21.64元，较前一交易日上涨2.08%，最新总市值为41.58亿元。公司近日发布《关于2025年第三次以集中竞价交易方式回购公司股份的进展公告》。公告显示，截至2025年11月21日，之江生物通过集中竞价交易方式累计回购股份1,012,181股，占公司当前总股本的0.53%。公司于2025年10月15日召开董事会审议通过回购方案，拟用于员工持股计划或股权激励，回购期限为2025年10月15日至2026年10月14日，预计回购金额为6,000万元至12,000万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400023604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2583541826","title":"每周股票复盘：之江生物（688317）股东会通过外汇衍生品交易议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2583541826","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583541826?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:57","pubTimestamp":1763240227,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，之江生物报收于23.5元，较上周的22.11元上涨6.29%。本周，之江生物11月14日盘中最高价报23.95元。本周关注点公司公告汇总：之江生物2025年第二次临时股东会审议通过《关于开展外汇衍生品交易业务的议案》，同意票占有效表决权股份总数的99.52%。浙江天册律师事务所确认会议合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2583686507","title":"之江生物（688317）披露公司开展外汇衍生品交易业务议案获股东会通过，11月14日股价上涨3.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583686507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583686507?lang=zh_cn&edition=full","pubTime":"2025-11-14 23:01","pubTimestamp":1763132468,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，之江生物报收于23.5元，较前一交易日上涨3.07%，最新总市值为45.16亿元。该股当日开盘22.81元，最高23.95元，最低22.7元，成交额达1.02亿元，换手率为2.25%。近日，之江生物发布2025年第二次临时股东会决议公告，宣布审议通过《关于开展外汇衍生品交易业务的议案》。出席本次股东会的股东共112人，代表表决权72,821,903股，占公司总表决权的41.1290%。议案获得普通决议通过，且对中小投资者进行了单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"2580143022","title":"之江生物（688317）披露首次回购股份进展，11月03日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580143022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580143022?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:36","pubTimestamp":1762180592,"startTime":"0","endTime":"0","summary":"截至2025年11月3日收盘，之江生物报收于22.76元，较前一交易日下跌0.91%，最新总市值为43.74亿元。截至2025年10月31日，公司暂未实施回购。本次回购符合相关规定及公司回购方案。公司将根据市场情况择机实施回购，并及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300036284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"gpt_icon":0},{"id":"1110221438","title":"三友生物与之江生物签署创新生物医药自动化研发战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1110221438","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110221438?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:16","pubTimestamp":1762179368,"startTime":"0","endTime":"0","summary":"三友生物与之江生物签署创新生物医药自动化研发战略合作协议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688317"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770547918098,"stockEarnings":[{"period":"1week","weight":-0.0527},{"period":"1month","weight":0.0416},{"period":"3month","weight":-0.0253},{"period":"6month","weight":-0.0767},{"period":"1year","weight":0.3132},{"period":"ytd","weight":0.0684}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海之江生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14435人(较上一季度减少7.74%)","perCapita":"13311股","listingDate":"2021-01-18","address":"上海市浦东新区张江高科技产业东区瑞庆路528号20幢乙号1层、21幢甲号1层","registeredCapital":"19215万元","survey":" 上海之江生物科技股份有限公司的主营业务是分子诊断试剂和仪器设备的研发、生产和销售。公司的主要产品是分子诊断试剂和仪器设备。公司共有500多项产品，已形成20大系列，是国内感染性疾病分子诊断产品最为齐全的企业之一，覆盖了绝大多数国家法定传染病。","listedPrice":43.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"之江生物(688317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供之江生物(688317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"之江生物,688317,之江生物股票,之江生物股票老虎,之江生物股票老虎国际,之江生物行情,之江生物股票行情,之江生物股价,之江生物股市,之江生物股票价格,之江生物股票交易,之江生物股票购买,之江生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"之江生物(688317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供之江生物(688317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}